Board meeting on 3 November 2026 to approve September quarter results
Genpharmasec Ltd has informed BSE that its Board of Directors will meet on Tuesday, 3 November 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Tuesday, 3 November 2026
- Results Period
- quarter and half year ended 30 September 2026
- Trading Window Closure
- closed from 1 October 2026 till 48 hours after the results are declared
What the update says
The company has informed BSE that a meeting of its Board of Directors will be held on Tuesday, 3 November 2026 at the registered office. The board will consider and approve, among other matters, the Un-audited Standalone and Consolidated Financial Results of the company along with the Limited Review Report for the quarter and half year ended 30 September 2026. The board may also take up any other business with the permission of the Chairman.
Why the second half of the year matters here
The results cover both the quarter (July to September 2026) and the half year (April to September 2026). Because the company reports on a standalone and a consolidated basis, two sets of numbers are expected, and both carry a Limited Review Report from the auditors.
Trading window
- The trading window for all directors, designated persons, their immediate relatives and specified connected persons has been kept closed for dealing in the company's securities from 1 October 2026.
- It will reopen 48 hours after the Un-audited Financial Results for the quarter and half year ended 30 September 2026 are declared.
- This is a routine restriction that runs around results announcements and covers insiders rather than ordinary shareholders.
What to look for next
- The actual financial results, which are still to be considered and approved by the board on 3 November 2026.
- The Limited Review Report that accompanies them.
- Any other business that the board approves at the same meeting.
How to read this
This is a scheduling notice, not a results announcement. It tells shareholders when the company's September quarter and half year numbers are expected to be taken up for approval, which helps them plan around that date.
Also from Genpharmasec
Q2 results, Clinigenome stake sale and company secretary resignation approved by the board
3 Nov 2026
Subsidiary renamed with FZCO suffix under revised DMCC naming rules
14 Oct 2026
More numbers
- Trading window reopens 48 hours after results are declared48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.